At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care.
- Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care
- Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets
- A strong portfolio of on-market products, and an extensive portfolio of pre-market assets
- An international biopharmaceutical company covering the entire value chain
- We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation
2010
Served areaWorldwide
Headcount1,509
HeadquartersTomtebodavägen 23A, 17165 Solna – Sweden
295,319,743
IPOSept. 15, 2006
Stock exchange(s)Nasdaq Stockholm